Justin Zelin
Stock Analyst at BTIG
(1.69)
# 3,423
Out of 5,147 analysts
42
Total ratings
29.55%
Success rate
-8.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Maintains: Buy | $6 → $9 | $9.78 | -7.98% | 2 | Jan 23, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $45 | $22.97 | +95.91% | 1 | Dec 10, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $21.71 | +157.95% | 5 | Dec 9, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Buy | $50 | $24.75 | +102.01% | 1 | Nov 10, 2025 | |
| TCRX TScan Therapeutics | Downgrades: Neutral | n/a | $1.06 | - | 2 | Nov 4, 2025 | |
| IPHA Innate Pharma | Reiterates: Buy | $8 | $1.72 | +366.47% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $62 | $32.20 | +92.55% | 3 | Oct 21, 2025 | |
| CAN Canaan | Reiterates: Buy | $8 | $0.49 | +1,519.76% | 1 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $33.84 | +269.39% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $1.38 | +407.25% | 3 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $5.72 | +249.65% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $29.69 | +41.46% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.01 | - | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $1.01 | +79,107.92% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $32.30 | +181.73% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $160 | $7.25 | +2,106.90% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.24 | +614.29% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $19.00 | +373.68% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $8.73 | +255.10% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $37.45 | -58.61% | 1 | Mar 28, 2023 |
ImmunityBio
Jan 23, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $9.78
Upside: -7.98%
ArriVent BioPharma
Dec 10, 2025
Initiates: Buy
Price Target: $45
Current: $22.97
Upside: +95.91%
Syndax Pharmaceuticals
Dec 9, 2025
Reiterates: Buy
Price Target: $56
Current: $21.71
Upside: +157.95%
Ascentage Pharma Group International
Nov 10, 2025
Initiates: Buy
Price Target: $50
Current: $24.75
Upside: +102.01%
TScan Therapeutics
Nov 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.06
Upside: -
Innate Pharma
Oct 29, 2025
Reiterates: Buy
Price Target: $8
Current: $1.72
Upside: +366.47%
IDEAYA Biosciences
Oct 21, 2025
Reiterates: Buy
Price Target: $62
Current: $32.20
Upside: +92.55%
Canaan
Oct 14, 2025
Reiterates: Buy
Price Target: $8
Current: $0.49
Upside: +1,519.76%
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $33.84
Upside: +269.39%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $1.38
Upside: +407.25%
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $5.72
Upside: +249.65%
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $29.69
Upside: +41.46%
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.01
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.01
Upside: +79,107.92%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $32.30
Upside: +181.73%
Aug 10, 2023
Maintains: Buy
Price Target: $320 → $160
Current: $7.25
Upside: +2,106.90%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $2.24
Upside: +614.29%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $19.00
Upside: +373.68%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $8.73
Upside: +255.10%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $37.45
Upside: -58.61%